Galapagos (GLPG)

Executive Summary

Galapagos is a Belgian biopharmaceutical company focused on developing innovative therapies in inflammation, fibrosis, and oncology. Its lead marketed product, Jyseleca (filgotinib), a JAK1 inhibitor, is approved in Europe for rheumatoid arthritis and ulcerative colitis. The company is strategically pivoting toward cell therapy, leveraging its acquisition of CellPoint to build a pipeline of CAR-T candidates targeting hematologic malignancies and solid tumors. Recent pipeline data has been mixed, with some early-stage trials completing and a Phase 2 study in systemic sclerosis terminated. Galapagos continues to invest in R&D, with a focus on portfolio diversification and maximizing the value of its core assets. The company's near-term growth hinges on successful execution of its cell therapy strategy and potential partnerships to advance its pipeline.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for leading CAR-T candidate (GLPG5101) in non-Hodgkin lymphoma60% success
• Q3 2026Regulatory decision on filgotinib for psoriatic arthritis in Europe (EMA review)80% success
• Q4 2026Potential partnership or out-licensing deal for early-stage fibrosis or inflammation program50% success